Leadership & Pay ·
TELA Bio, Inc. filed an amendment to disclose the separation agreement with former CEO Antony Koblish, effective…
TELATELA Bio, Inc.
TELA Bio, Inc. filed an amendment to disclose the separation agreement with former CEO Antony Koblish, effective August 7, 2026. Mr. Koblish ceased serving as CEO on August 3, 2026. Under the agreement, he receives twelve months of base salary paid ratably over one year and twelve months of COBRA premium coverage. All his equity awards immediately accelerate and vest upon the effective date. Performance stock units remain eligible to vest based on revenue and gross margin goals achieved by December 31, 2026, or at target if a change in control occurs before that date. The option exercise period is extended until December 31, 2027. TELA Bio operates in the biotechnology industry, developing medical devices for wound care.